Immunotherapy for psoriasis: from serendipity to selectivity.
Griffiths
Christopher E M
CE
Dermatology Centre, University of Manchester School of Medicine, Hope Hospital, Salford, Manchester M6 8HD, UK. christopher.griffiths@man.ac.uk
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D006801:Humans; D007167:Immunotherapy; D000069285:Infliximab; D008213:Lymphocyte Activation / Q000187:drug effects; D011565:Psoriasis / Q000276:immunology / Q000628:therapy*; D015375:Receptors, Interleukin-2 / Q000037:antagonists & inhibitors* / Q000276:immunology; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors* / Q000276:immunology
D000911:Antibodies, Monoclonal; D015375:Receptors, Interleukin-2; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab